Sustainability & Climate

Evvy's new at-home UTI test promises fast, precise results. But can its high-tech, high-cost model truly revolutionize women's healthcare?

Beyond transmissions, Allison's deep investment in India is a blueprint for global firms fueling defense, mining, and export growth. Here's why it matters.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Beyond e-commerce, GigaCloud's massive new NJ facility signals a strategic move to fortify trans-pacific supply lines for large goods, impacting US economic competitiveness.

A mandatory disclosure from a Boston investment giant reveals its position in a $1.4B merger. What does it signal for the future of the auto industry?

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Tabletop giant Asmodee is raising €320M. We decode the complex financial strategy and reveal how it fortifies its vast global supply chain.

Facing a fiscal crunch, San Diego County's move to a cloud-based budget system offers a model for data-driven efficiency and public service reform.

Dr. Timothy Lubenow's move from a top university to a community clinic highlights a trend that's making advanced medical care more accessible.

Beyond the award, Pariveda's use of generative AI to modernize legacy systems reveals a powerful new playbook for enterprise transformation and value.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Granted a tight deadline by Nasdaq, Triller Group must fix its finances and failing stock price or face delisting. Is its hybrid social media-fintech model viable?

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

The platform's 2025 report reveals more than just charity; it's a real-time indicator of economic distress, disaster response, and tech-driven mutual aid.

CityHealth's 2025 report shows local policy is potent medicine. Discover how cities like Chicago are using data to tackle health, from housing to greenspace.

As Malaysia's economic boom fuels urban traffic pollution, a new market for in-home health tech is emerging. Can companies like Levoit turn this risk into a strategic win?

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?